CAM
VYGR icon

ClariVest Asset Management’s Voyager Therapeutics VYGR Stock Holding History

ClariVest Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$813K Hold
102,822
– – 0.08% 292
2024
Q2 		$813K Buy
102,822
+2,699
+3% +$22.6K 0.08% 292
2024
Q1 		$932K Buy
100,123
+37,275
+59% +$315K 0.1% 278
2023
Q4 		$530K Buy
62,848
+13,548
+27% +$98.3K 0.03% 357
2023
Q3 		$382K Hold
49,300
– – 0.02% 361
2023
Q2 		$564K Buy
+49,300
New +$510K 0.03% 335

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClariVest Asset Management's VYGR Position: Q3 2024 in Review

ClariVest Asset Management held its Voyager Therapeutics (VYGR) position steady in Q3 2024 at 102,822 shares worth $813K. The position accounts for 0.08% of the portfolio, ranked #292.

ClariVest Asset Management first reported a position in VYGR in Q2 2023 and has held it in 6 quarters since. The position peaked at $932K in Q1 2024. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • ClariVest Asset Management held 102,822 shares of Voyager Therapeutics worth $813K as of Q3 2024.
  • ClariVest Asset Management left its Voyager Therapeutics share count unchanged in Q3 2024.
  • Voyager Therapeutics made up 0.08% of ClariVest Asset Management's portfolio in Q3 2024, its #292 holding.
  • ClariVest Asset Management first reported a position in Voyager Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • ClariVest Asset Management's Voyager Therapeutics position peaked at $932K in Q1 2024.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.